Eskens F A, Roelofs E J, Hermus A R, Verhagen C A
Department of Medicine, University Hospital Nijmegen, The Netherlands.
Anticancer Res. 1997 Nov-Dec;17(6D):4667-70.
A patient with a pancreatic islet cell tumor concurrently producing vasoactive intestinal polypeptide (VIP) and calcitonin with related symptoms is presented. The patient was given palliative treatment consisting of octreotide, streptozotocin and 5-fluorouracil, and survival now exceeds 72 months. The concurrent production of VIP and calcitonin by a pancreatic islet cell tumor has not been described before.